Supported by an educational grant from Neurocrine Biosciences, Inc.

Homepage

Featured

Videos

Anticholinergics and VMAT-2 Inhibitors: Different MOAs, Different Results

Videos

Unpacking the Patient Experience of Living With Tardive Dyskinesia

Faculty

Craig Chepke, MD, DFAPA

Medical Director,
Excel Psychiatric Associates

Rakesh Jain, MD, MPH

Clinical Professor,
Texas Tech - Permian Basin

Desiree Matthews, PMHNP-BC

CEO,
Different MHP, PC

Jonathan Meyer, MD

Voluntary Clinical Professor of Psychiatry,
University of California,
San Diego School of Medicine

Education

Moving Mountains with Molecules in Tardive Dyskinesia: Optimizing Strategies for Challenging Cases

Videos

Telehealth AIMS Demo

Anticholinergics and VMAT-2 Inhibitors: Different MOAs, Different Results

AIMS Severity Assessment Video Library

Podcasts

TD in Community Psychiatry: A Hidden Epidemic?

Monitoring TD in Long-Term Care or Geriatric Populations

Shared Decision-Making in TD

News

Valbenazine Effective for Long-Term Treatment of TD in Older Adults, Analysis Finds

Deutetrabenazine Targets VMAT2 With Precision, Analysis Finds

Patient Survey Identifies Barriers to TD Treatment

Posters

Patient Perspective on Barriers to Diagnosis and Treatment of Tardive Dyskinesia: Results From a Cross-Sectional Survey

Impact of Tardive Dyskinesia on Clinical Aspects and Quality of Life Based on Individuals’ Underlying Psychiatric Conditions: Interim Analysis of Baseline Data From the IMPACT-TD Registry

Once-Daily Valbenazine for Tardive Dyskinesia or Huntington’s Disease Chorea in Patients with Dysphagia or Swallowing Difficulties